3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Glioblastoma
18
Brain Neoplasms
8
Lymphoma
6
Central Nervous System Neoplasms
6
Medulloblastoma
4
Glioma
4
Astrocytoma
4
Recurrence
3
Neoplasms
2
Lymphoma, Non-Hodgkin
2
Lymphoma, AIDS-Related
2
Lung Neoplasms
2
Uveal Melanoma
1
Spinal Cord Neoplasms
1
Solid Tumor
1
Sarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Neoplasm Metastasis
1
Melanoma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Leukemia-Lymphoma, Adult T-Cell
1
Kidney Neoplasms
1
Intraocular Lymphoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Gliosarcoma
1
Interventions
apatinib
3
vistusertib
2
olaparib
2
camrelizumab
2
atezolizumab
2
Ipilimumab
2
Everolimus
2
trametinib
1
toripalimab
1
tilsotolimod
1
tazemetostat
1
tazarotene
1
spartalizumab
1
seviteronel
1
sargramostim
1
sacituzumab govitecan
1
rucaparib
1
roniciclib
1
romiplostim
1
pyrotinib
1
phosphorylethanolamine
1
pemigatinib
1
pembrolizumab
1
pazopanib
1
palbociclib
1
niraparib
1
magrolimab
1
lenvatinib
1
irinotecan sucrosofate
1
famitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Solid Tumor
×
Lomustine
×
Clear all
NCT05898451
2023-06-12
R-2
Refnot-Pharm Ltd
Phase 2
Completed
55 enrolled